Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

A small, early-stage study published in the journal Headache suggested a diabetes drug may ease migraines by lowering ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Now, a study ... in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. This type of study ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk to addiction treatment. Now new research out of ...